Advances in stroke pharmacology

Zhenhua Zhou, Jianfei Lu, Wen Wu Liu, Anatol Manaenko, Xianhua Hou, Qiyong Mei, Jun Long Huang, Jiping Tang, John H. Zhang, Honghong Yao, Qin Hu

Research output: Contribution to journalArticlepeer-review

Abstract

Stroke occurs when a cerebral blood vessel is blocked or ruptured, and it is the major cause of death and adult disability worldwide. Various pharmacological agents have been developed for the treatment of stroke either through interrupting the molecular pathways leading to neuronal death or enhancing neuronal survival and regeneration. Except for rtPA, few of these agents have succeeded in clinical trials. Recently, with the understanding of the pathophysiological process of stroke, there is a resurrection of research on developing neuroprotective agents for stroke treatment, and novel molecular targets for neuroprotection and neurorestoration have been discovered to predict or offer clinical benefits. Here we review the latest major progress of pharmacological studies in stroke, especially in ischemic stroke; summarize emerging potential therapeutic mechanisms; and highlight recent clinical trials. The aim of this review is to provide a panorama of pharmacological interventions for stroke and bridge basic and translational research to guide the clinical management of stroke therapy.

Original languageEnglish
Pages (from-to)23-42
Number of pages20
JournalPharmacology and Therapeutics
Volume191
DOIs
StatePublished - Nov 2018

ASJC Scopus Subject Areas

  • Pharmacology
  • Pharmacology (medical)

Keywords

  • Animal studies
  • Clinical trials
  • Neuroprotection
  • Pharmacology
  • Stroke
  • Brain Ischemia/drug therapy
  • Humans
  • Stroke/drug therapy
  • Drug Development/methods
  • Molecular Targeted Therapy
  • Neuroprotective Agents/pharmacology
  • Animals
  • Translational Research, Biomedical/methods

Cite this